Sign in
TerminatedPhase 1/2

NG2 and DLL3 CAR-T Cells Targeting Melanoma

Key facts

Who runs it
Shenzhen Geno-Immune Medical Institute
Where
China1 site in 1 countryChoose a country to see its sites
Trial code
Status
Terminated
Phase
Phase 1/2
People taking part
100 people enrolled
Started
1 Sept 2025
Ended
31 Jul 2026
Type of study
Interventional
Treatments tested
  • NG2 and DLL3 CAR-T cells
Record updated
3 November 2026

Who can take part

Age
18 years to 75 years
Sex
Women and men
Healthy volunteers
Cannot take part
Show the full registry criteria (22)Hide the full registry criteria

Who can take part

  • Patients with tumors have received standard first-line therapy and have been diagnosed with non-resectable, metastatic, progressive or recurrent conditions
  • The expression status of NG2 and DLL3 antigens of the tumor has been determined for eligibility. Positive expression is defined by NG2 and DLL3 antibody staining results based on immunohistochemistry or flow cytometry analyses
  • Body weight greater than or equal to 40 kg
  • Age: ≥18 year and ≤ 75 years of age at the time of enrollment
  • Life expectancy: at least 8 weeks
  • Prior Therapy:; There is no limit to the number of prior treatment regimens. Any grade 3 or 4 non-hematologic toxicity of any previous therapy must have resolved to grade 2 or less; Participants must not have received hematopoietic growth factors for at least 1 week prior to mononuclear cells collection; At least 7 days must have elapsed since the completion of therapy with any biologic agent, targeted agent, tyrosine kinase inhibitor or metronomic non-myelosuppressive regimen; At least 4 weeks must have elapsed since prior therapy that includes a monoclonal antibody; At least 1 week must has elapsed since any radiation therapy at the time of study entry
  • Karnofsky/jansky score of 70% or greater
  • Cardiac function: Left ventricular ejection fraction greater than or equal to 40/55 percent
  • Pulse Ox greater than or equal to 90% on room air
  • Liver function: defined as alanine transaminase (ALT) <3x upper limit of normal (ULN), aspartate aminotransferase (AST) <3x ULN; serum bilirubin and alkaline phosphatase <2x ULN
  • Renal function: Patients must have serum creatinine less than 3 times ULN
  • Marrow function: White blood cell count ≥1000/ul, Absolute neutrophil count ≥500/ul, Absolute lymphocyte count ≥500/ul, Platelet count ≥25,000/ul (not achieved by transfusion)
  • Patients with known bone marrow metastatic disease will be eligible for study as long as they meet hematologic function criteria, and the marrow disease not evaluable for hematologic toxicity
  • For all patients enrolled in this study, their parents or legal guardians must sign an informed consent and assent

Who cannot take part

  • Untreated central nervous system (CNS) metastasis; patients with previous CNS tumor involvement that has been treated and is stable for at least 6 weeks following completion of therapy are eligible
  • Previous treatment with other genetically engineered CAR T cells
  • Patients who require systemic corticosteroid or other immunosuppressive therapy
  • Existing severe illness (e.g. significant cardiac, pulmonary, hepatic diseases, etc.) or major organ dysfunction, with the exception of grade 3 hematologic toxicity
  • Active HIV, Hepatitis B virus (HBV), Hepatitis C virus (HCV) infection or uncontrolled infection
  • Evidence of tumor potentially causing airway obstruction
  • Inability to comply with protocol requirements
  • Insufficient availability of CART cells

Where is this trial?

It has sites in one country. Choose a country to see its sites.

About the trial

What the trial wants to find out

The purpose of this study is to assess the feasibility, safety and efficacy of multiple CAR-T cell therapy which targets NG2 and DLL3 surface antigens in patients with relapsed and refractory melanoma.

The group in the trial

  • effectiveness of CAR-T cells targeting NG2 and DLL3Treatment being tested

    Gene-modified T cells are designed to kill tumor cells through specific recognition of NG2 and DLL3. This study will evaluate the side effects and effective doses of NG2 and DLL3 CAR-T cells in treating refractory and recurrent melanoma

    Treatment: NG2 and DLL3 CAR-T cells

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
Safety and Efficacy of NG2 and DLL3 CAR-T Therapy Targeting Melanoma
Record updated
3 November 2026